Certara, Inc. $CERT Stock Position Boosted by Kopion Asset Management LLC
by Renee Jackson · The Cerbat GemKopion Asset Management LLC boosted its holdings in Certara, Inc. (NASDAQ:CERT – Free Report) by 49.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 982,710 shares of the company’s stock after purchasing an additional 327,064 shares during the quarter. Certara comprises 6.2% of Kopion Asset Management LLC’s investment portfolio, making the stock its 8th largest holding. Kopion Asset Management LLC owned 0.62% of Certara worth $8,658,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of CERT. First Horizon Corp acquired a new stake in shares of Certara during the third quarter worth $30,000. Versant Capital Management Inc grew its position in Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after buying an additional 1,153 shares during the last quarter. Osaic Holdings Inc. increased its stake in Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in Certara in the 2nd quarter valued at $59,000. Finally, Global Retirement Partners LLC raised its position in Certara by 45.0% during the 3rd quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock worth $69,000 after buying an additional 1,749 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on CERT shares. Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 target price for the company. in a research note on Friday, February 27th. Leerink Partners reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Certara in a report on Thursday, February 26th. TD Cowen reiterated a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Morgan Stanley reduced their target price on Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Finally, Stephens decreased their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.10.
Certara Trading Down 1.8%
NASDAQ CERT opened at $6.38 on Friday. The company has a market cap of $1.02 billion, a P/E ratio of -638.00 and a beta of 1.50. Certara, Inc. has a 12 month low of $6.04 and a 12 month high of $15.38. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. The company has a 50-day moving average of $7.74 and a 200-day moving average of $9.49.
Certara (NASDAQ:CERT – Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. During the same period last year, the business posted $0.15 earnings per share. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.
Certara Profile
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.
Featured Stories
Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).